Glioblastoma Mulitforme (GBM), a malignancy of the glioblast stem cells of the brain, is one of the most aggressive and untreated forms of brain cancer. For most glioblastoma patients, there are only three treatment options: surgery, radiation, chemotherapy, or the combination of these treatments. Many patients choose chemotherapy, however most GBM cases show little to no response to Temozolomide (TMZ), which is a common chemotherapy drug used for this type of cancer. In some recent studies, researchers noticed elevated amounts of an enzyme, Inosine 5’-monophosphate dehydrogenase (IMPDH). This enzyme is known for DNA repair but in many GBM cases, due to its overproduction, it repairs rapidly and does not allow TMZ to terminate the cancerous tumors. In our research, we have been investigating whether the chemotherapeutic agent directly causes the increase in expression or if it is a unique property of this GBM cell type.

Investigating chemotherapeutic resistance: Why is glioblastoma so deadly?

Macromolecular Chemistry: The Second Century

[Author Benefits](https://scimeetings.acs.org/?utm_source=pubs_content_marketing&utm_medium=website&utm_campaign=0320_MCF_NPI_Launch_Spring_Homepage&ref=pubs_content_marketing)

[How to use SciMeetings](https://storage.googleapis.com/dl.morressier.com/acs/SciMeetings-ACSSpring2020-HowToGuide_M3020-Final.pdf)

[Frequently Asked Questions](https://storage.googleapis.com/dl.morressier.com/acs/SciMtng_ACSNMSp2020_FAQ_M3120_Final.pdf)

ACS Spring 2020 National Meeting & Expo

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.